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Dendritic cells (DCs) that drain the gut and skin are known to favor the establishment
of T cell populations that home to the original site of DC-antigen (Ag) encounter by
providing soluble “imprinting” signals to T cells in the lymph node (LN). To study the
induction of lung T cell-trafficking, we used a protein-adjuvant murine intranasal and
intramuscular immunization model to compare in vivo-activated Ag+ DCs in the lung
and muscle-draining LNs. Higher frequencies of Ag+ CD11b+ DCs were observed in
lung-draining mediastinal LNs (MedLN) compared to muscle-draining inguinal LNs (ILN).
Ag+ CD11b+ MedLN DCs were qualitatively superior at priming CD4+ T cells, which then
expressed CD49a and CXCR3, and preferentially trafficked into the lung parenchyma.
CD11b+ DCs from the MedLN expressed higher levels of surface podoplanin, Trem4,
GL7, and the known co-stimulatory molecules CD80, CD86, and CD24. Blockade
of specific MedLN DC molecules or the use of sorted DC and T cell co-cultures
demonstrated that DC surface phenotype influences the ability to prime T cells that then
home to the lung. Thus, the density of dLN Ag+ DCs, and DC surfacemolecule signatures
are factors that can influence the output and differentiation of lung-homing CD4+ T cells.
Keywords: CD11b+ dendritic cells, lung CD4+ T cells, lung homing, tissue imprinting, costimulation, vaccination
route
INTRODUCTION
Protection againstmajor human respiratory pathogens, such asMycobacterium tuberculosis (MTB),
Bordetella pertussis or influenza viruses would benefit from the persistence of lung effector T cells
and/or the rapid reactivation of lung resident memory T cells. Yet, the global mechanisms that
initiate enhanced trafficking to the airways are not well-characterized. Most vaccines administered
via the parenteral route elicit inferior airway mucosa immune responses compared to those
administered via the intranasal (i.n.) or intrapulmonary routes, although examples of the contrary
exist, reviewed in (1, 2). Therefore, a better understanding of how lung-trafficking T cells are
induced in vivo could guide the rational design of vaccine formulations (3) and immunotherapeutic
strategies (4) that provide the desired tissue “imprinting” signals (5) to T lymphocytes.
Cell surface profiles of pulmonary T cells have been defined previously in mice and humans,
and include elevated expression of one or more of the receptors: BLT-1, CCR1, CCR3, CCR4,
CCR5, CCR6, CCR8, CXCR3, CXCR4, CXCR6, CD69, CD103, LFA-1, PSLG-1, or VLA-1
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(3, 6–13). The majority of these markers have not been proven
to mediate lung-trafficking or retention per se, but serve as
surrogate markers given their increased expression by lung T
cells. Among them, CXCR3 and CD49a (integrin α1 subunit) are
being used increasingly as lung homing T cell markers. CXCR3
mediates chemotaxis toward inflamed tissues (14) including
the lung (15). During influenza infection, the CXCR3-CXCL10
(IP-10) axis appears critical for the recruitment of pulmonary
CD8+ T cells that control the infection (16). Similarly, MTB
infection or immunization can induce protective CXCR3+ CD4+
T cells that readily enter the lung parenchyma (17, 18). CD49a
appears to allow more selective trafficking into respiratory
and reproductive tissues (3, 6), supporting an important role
for adhesion molecules in the control of tissue tropism (11).
CD49a has been additionally described to play a role in lung
tissue retention in humans, alongside other molecules, such as
CD69 (12).
Dendritic cells (DC) mediate critical roles in shaping T cell
responses—including tissue-specific T cell imprinting (19, 20).
For example, soluble vitamin A and D derivatives produced by
intestine or dermis-draining DCs, respectively upregulate gut
and skin homing markers on murine T cells (21–23), and similar
imprinting mechanisms are likely to be at play in humans (24–
28). Less is known about the contribution of tissue-specific
DC surface markers to T cell tissue-homing. In general, DC
stimulatory signals influence many features of newly primed
T cells, reviewed in (29), including differentiation into effector
vs. memory cells (30) or various T-helper (Th) subsets (31).
For instance, cell surface TCR and CD28-mediated signaling
rapidly induce tissue-adhesion molecules, such as P- and E-
selectin on T cells (32). Furthermore, binding of DC-expressed
CD80 with CTLA-4 contributes to the induction of LFA-1 on
T cells, which can mediate mucosal tissue retention (33). T cell
homing markers, including those that allow trafficking into the
lung, may thus be modulated by surface DC:T cell interactions
during priming. Initial evidence of DC-mediated imprinting of
lung-homing markers on T cells has been demonstrated using
murine DCs from the MedLN that were pulsed with Ag (34).
The in vitro primed T cells expressed higher levels of CCR4 and
showed an enhanced capacity to migrate into the lung compared
to cells primed by DCs from other LNs.
In the mouse lung, reports have described two major
conventional (cDC) DC subsets distinguished by their surface
phenotype (35, 36). The airways are rich in CD103+ type 1
cDC (cDC1) which extend their dendrites into alveolar spaces,
and CD11b+ type 2 cDC (cDC2) are usually present in higher
numbers throughout the parenchyma (36, 37). In contrast,
murine lymph node (LN)-resident cDC1 and cDC2 typically
express CD8+ and CD4+, respectively, a fraction of LN cDC2
express CD11b, and CD103 is exclusively expressed by non-
lymphoid resident (migratory) DCs (38–40). Lung resident DCs
Abbreviations: dLN, draining lymph node; gMFI, geometric mean fluorescence
intensity; ILN, inguinal lymph node; i.m., intramuscular; i.n., intranasal; i.v.,
intravenous; MedLN, mediastinal lymph node; OT-II, OVA323−339 peptide specific
CD4+ T cell; OVA, chicken ovalbumin protein; PDPN, podoplanin; t-SNE,
t-distributed stochastic neighbor embedding.
that have migrated to the MedLN are more mature, more potent
T cell activators (41), and better inductors of lung-homing T cells
(34) than LN-resident DCs.
In the current study, we assessed the cellular and molecular
mechanisms that contribute to the induction of lung-homing
CD4+ T cells. To reduce the experimental artifacts that are
typically associated with ex vivo DC manipulation, we employed
an immunization model comparing the intranasal (i.n.) and
intramuscular (i.m.) routes, activating and loading DCs in vivo
using various adjuvants. We demonstrate the involvement of
a DC subset that is enriched in the MedLN and capable of
priming lung-tropic CD4+ T cells. We subsequently characterize
the unique surface features of this cell subset to identify some of
the mechanisms at play.
MATERIALS AND METHODS
Mice
C57BL/6J mice (BL6) and C57BL/6-Tg (TcraTcrb) 425Cbn/Crl
CD45.1 (“OT-II,” OVA323−339 TCR transgenic) were purchased
from Charles River (Ecully, France), and Rag2−/− mice were
a kind gift from the laboratory of Prof. Walter Reith at the
University of Geneva, Switzerland. Mice were bred or housed
in pathogen-free animal facilities at the University of Geneva in
accordance with local guidelines. Experiments were comprised of
all male cohorts at 6–8 weeks of age unless otherwise indicated,
and conducted in accordance with the Geneva veterinary office,
and European guidelines.
Antibodies
The following flow cytometry detection reagents were sourced
from the indicated manufacturers, Biolegend (CA, USA):
anti-mouse MHC-II (I-A/I-E, clone M5.114.15.2:PE-CF594,
or PerCP-Cy5.5), CD11c (clone N418:PE-Cy7), CD49a (clone
HMa1:APC) CD86 (clone GL1:PerCP-Cy5.5), podoplanin
(PDPN, clone 8.1.1:APC), CD11b (clone M1/70:APC-Cy7 or
BV421), CD24 (clone M1/69:PE or BV421, clone SN3:PerCP
eFluor710), CXCR6 (CD186, clone SA051D1:PE), CCR4
(CD194, clone 2G12:PE), CD103 (clone 2E7:PE or BV510),
B220 (clone RA3-6B2:BV711), CD64 (clone X54-5/7.1:APC),
CXCR3 (CD183, clone CXCR3-173:PE), CD62L (clone Mel-
14:PerCP-Cy5.5), CD44 (clone IM7:APC-Cy7), CXCR4 (CD194,
clone L276F12:BV421), CD45.1 (clone A20:BV650, FITC, or
Pacific Blue), CD45.2 (clone 104:APC-Cy7 or PE-Cy7). Becton
Dickenson (BD, NJ, USA) and BD Pharmingen (SJ, USA): CD19
(clone 1D3:BUV737), CD4 (clone RM4-5:BV786), B220 (clone
RA3-6B2:PECF594), CD69 (clone H1.2F3:PE-CF594), CD49a
(clone HA31/8:BV510). eBioscience (SC, USA): CD45 Ab (clone
30-F11: PECy7), CXCR5 (clone SPRCL5:PeCy7), α4β7 (LPAM1,
clone DATK32:APC).
Immunization and Injections
Mice were immunized with 40 µl of sterile PBS containing
the indicated immunogen and adjuvant admixture, either by
the i.n. route using a micropipette, or the i.m. route in one
thigh muscle using a 30G needle and syringe. The immunogen
admixtures comprised of one or more of the following as
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indicated in the Figure legends: endotoxin free ovalbumin (OVA)
protein (Invivogen, SJ, USA); 20 µg, ovalbumin Alexa Fluor 488
conjugate (‘fluorescent OVA’, Invitrogen): 8 and 20 µg of one
of the following TLR agonists (Invivogen) Poly(I:C), CpG 1826,
or LPS.
For in vivo staining to distinguish total leukocytes in the
lung vasculature compared to the lung parenchyma, described
elsewhere in detail (42), anti-CD45 Ab (clone 30-F11: PECy7,
eBioscience) was diluted 1/50 in sterile PBS (Sigma, SL, USA) and
injected i.v. into anesthetized mice. Mice were sacrificed exactly
2min after, lungs were removed immediately, and processed
as described below without prior perfusion. When indicated,
detection of CD45.1+ OT-II cells during the ex vivo surface
staining procedure was performed using anti-CD45.1 Ab (clone
A20: Pacific Blue, Biolegend).
Tissue Harvesting and Cell Preparation
After euthanasia via CO2 inhalation, the LNs or spleens were
removed, dissociated using a mortar and pestle, digested with 1
µg ml −1 Liberase TL (Roche, Basel, Switzerland) and 1mg ml
−1 DNase I (Sigma-Aldrich) in serum free media for 30min at
37◦C. Single-cell suspensions were filtered, counted, and washed
in DC media (RPMI 1640 media (Invitrogen) supplemented
with 10% heat-inactivated (HI) FCS (Pan Biotech, Germany),
25mM HEPES, 50U ml −1 penicillin (Gibco, MA, USA), 50
µg ml −1 streptomycin (Gibco), 50µM 2-mercaptoethanol,
sodium pyruvate 1mM (Sigma), non-essential amino acids at
the recommended dilution (Gibco) and 2mM EDTA (Sigma),
before staining for cytometry. When necessary, red blood cell
lysis was performed using ACK buffer (BD) for 2min at
room temperature.
Lung tissue was minced and then digested using 5ml of
serum-free RPMI containing 350 enzyme activity units of
Collagenase IV (Worthington Biochem, NJ, USA) and 5mg of
DNase I, and incubated for 30min at 37◦C before being passed
through a 20µm filter, washed, counted, subjected to RBC lysis,
and then plated similarly to other tissues.
Cell Enrichment or Depletion
OT-II cells used for in vitro co-culture and in vivo transfer
experiments were enriched from the spleens of naïve OT-II mice
using a negative selection “naïve CD4+ T cell enrichment kit”
(Miltenyi, Germany). Purity was consistently between 88 and
96% CD4+ cells, with >99% of these cells being CD44−, as
confirmed by flow cytometry.
CD3+, and or CD19+ cells were sometimes depleted from LN
single cell suspensions using positive selection magnetic bead-
based cell enrichments kits MACS kits (Miltenyi) as described in
the manufacturer protocol.
Flow Cytometry Staining, Acquisition, and
Cell Sorting
One to three million cells were added to 96-well V-bottom
plates (ThermoScientific, MA, USA) and washed in RT PBS,
then incubated at RT for 10min in one of the following viability
dyes diluted 1/1,000 in RT PBS; LIVE/DEAD Fixable Blue
or Aqua (Invitrogen), or Zombie Yellow Fixable Viability Kit
(Biolegend). Cold conditions and reagents (1–4◦C) were used
for the following steps. Wells were completed with FACS buffer
[“FB,” comprising of PBS, with 2% FCS, and 0.05% azide (Sigma)]
containing 50 µg ml −1 Fc block (mAb 2.4G2), centrifuged, re-
suspended in cocktails of fluorescently-tagged Abs or isotype-
control Abs for 20min, before washing in FB, fixed for 20min
using a FoxP3 fixation kit (eBioscience) as per the manufacturers’
recommendations. Cells were then washed in FB and acquired
using an HTS plate reader and LSRFortessa cytometer (BD). To
more accurately enumerate cell numbers, samples were spiked
with set amounts of 10µm Coulter CC latex beads (Beckman
Coulter) during the staining procedure. To determine cell size,
the TaliTM image-based cytometer (Beckman Coulter) was used
to acquire between 200 and 375 events from (i) sorted DC subsets
that had been rested overnight in complete media, at 37◦C with
5% CO2, (ii) MACS-purified naïve OT-II cells, or (iii) 10µm
Coulter CC latex beads. Dead cells were excluded using a viability
dye and doublets were removed during the analysis.
Screening of DC surface proteins made use of the Biolegend
LEGENDScreen R© Lyophilized Ab Array containing 255 PE-
conjugated Abs specific for mouse cell markers, including 11
isotype-matched control PE-conjugated Abs (see Figure 4D and
Table S1), performed as per the manufacturers’ instructions.
Flow cytometric sorting of DCs was performed at the
University of Geneva Flow Cytometry Platform, using a MoFlow
Astrios flow cytometer. DC suspensions were optionally depleted
of CD19+ and CD3+ lymphocytes as described above to increase
the sorting rate. Cell suspensions were stained with fluorescent
Abs that were specific for leukocyte lineage markers, then diluted
in azide-free FACS buffer and sorted into tubes containing
complete media using the following gates; singlets, live, SSC
vs. FSC for DC morphology, exclusion of autofluorescent and
CD64hi cells [macrophages and inflammatory monocytes (43)],
exclusion of NK1.1+ (NK cells), B220+ (B cells and plasmacytoid
DCs), and CD3+ cells, followed by positive selection of the
desired DC population usingmarkers includingMHC-II, CD11c,
CD103, CD11b, and CD24. Sorted DC subsets were routinely
>99% pure, and were washed before being used immediately in
T cell co-culture assays.
Flow Cytometry Analysis
The net geometric mean fluorescence intensity (gMFI) in the
LEGENDScreen R© analysis was calculated by subtracting the
background PE fluorescence, which was obtained using either
a PE-conjugated isotype control Ab or fluorescence-minus-one
staining control (full Ab panel in the absence of a PE-conjugated
Ab). The ratio of gMFI was calculated by dividing the net PE
gMFI of OVA+ CD11b+ MedLN DCs by the net PE gMFI of
OVA+ CD11b+ ILN DCs.
Principal Component Analysis was performed with 500
randomly selected Ag+ CD11b+ conventional DC events, from
each of two draining LN sites immunized mice, using FCS
Express 6 software.
t-SNE analysis was performed using Flowjo software (Tree
Star, USA). Briefly, a total of 2,500 randomly selected Ag+
CD11b+ conventional DC events, from the draining ILN
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and MedLN of immunized mice were concatenated. The t-
SNE dimensionality reduction was performed using these
5,000 concatenated cells and the following parameters: theta
= 0.5, eta = 200, perplexity = 20, and iterations = 1,000,
and the expression of CD86, CD24, PDPN, and GL7. These
parameters were defined empirically and selected because they
resulted in adequate separation between cell sub-phenotypes
on the bivariate t-SNE “x” vs. t-SNE “y” plot. Nine gates
were drawn on the bivariate t-SNE plot to further analyze
marker expression within the major sub-phenotypes using
histograms, including in comparison to conventionally gated
non-DC control subsets; B (CD19+CD11c−CD4−) or CD4+
lymphocytes (CD4+CD3+MHC-II−).
In vitro DC/T Cell Co-cultures
MACS-purified OT-II cells and cytometry-sorted DCs were
plated in 96-well U-bottom plates (ThermoScientific, MA, USA)
in 100 µl of DC culture media (EDTA-free) at a ratio of 20 to 1,
comprising of 5,000 DCs and 100,000 OT-II cells per well, in the
absence of exogenous cytokines or antigens. The co-culture was
maintained in a humidified incubator for 1–3 days at 37◦C with
5% CO2. Co-cultures were performed using DCs and OT-II cells
from gender and age-matched mice.
Blockade of DC surface markers during co-culture was
achieved by incubating 5,000 sorted DCs in 10 µg ml −1
(saturating concentrations) of one of the following purified
mAbs: rat IgG2b anti-CD24 (clone M1/69), rat IgM anti-GL7
(clone GL7), Syrian hamster IgG anti-PDPN (clone 8.1.1), rat
IgG2a anti-CD86 (clone GL1), or matched isotype control
mAbs, for 20min on ice, before washing the cells, co-culturing
with 100,000 OT-II cells and staining for flow cytometry as
described above.
In vivo T Cell Trafficking
MACS-purified naïve OT-II cells (200,000 per mouse) were
transferred via the i.v. route into naïve age and gender-matched
BL6 recipients before immunization as described above. Ten days
later, in vivo staining of vascular/parenchymal lung leukocytes
was performed followed by ex vivo staining of OT-II cells and
characterization of the T cell response by flow cytometry, all as
described above.
To compare the imprinting capacity of DCs in the absence
of other cells and on a “per-cell” basis, a competitive adoptive-
transfer T cell assay was performed using naïve OT-II cells that
were activated for 3 days using in vitro co-culture with sorted
Ag+ CD11b+ DCs from immunized mice, as described above. As
an additional comparison, naïve OT-II were activated using Ag−
CD11b+ DCs from the dLNs of immunized mice, which were
pulsed with 0.1 µg ml −1 OT-II peptide (OVA323−339, Invivogen)
in complete media for 30min, and washed twice, before co-
culture. After 3 days of activation by co-culture with OVA+ DCs
or OVA− Ag-pulsed DCs, a live cell count was performed, and
OT-II cells were adjusted to 5 million ml −1 in PBS containing
0.1% bovine serum albumin (BSA, Sigma Aldrich). Cells from
different co-cultures were stained with either high (20µM) or
low (0.5µM) concentrations of CFSE (Molecular Probes) in PBS
containing 0.1% BSA, for 10min at 37◦C, before quenching with
an equal volume of cold HI FCS. Live CFSEhigh and CFSElow
stained cells were mixed at a 1:1 ratio. One hundred thousand
cells from each DC site co-culture (200,000 per mouse) were
injected i.v. using a 30G syringe into the tail vail of anesthetized
recipient Rag2−/− mice, which were matched in terms of age and
gender to the co-culture cell donor mice. After 18 h, in vivo and
ex vivo staining was performed to enumerate and characterize
OT-II cells in the lung parenchyma vs. lung circulation, spleen
and dLNs, as described above. The tissue homing index is the
number of CD44+ OT-II cells in a given tissue compartment that
were originally primed by MedLN DCs, divided by the number
of CD44+ OT-II cells in the same tissue originally primed by ILN
DCs. This index was normalized because different proportions
of CD44+ cells were present in the 1:1 mixture (based on total
live cells) of MedLN and ILN DC-primed co-cultures prior to
transfer. Normalization involved division of each homing index
value by the % CD44+ of total OT-II cells from each co-culture
type in the 1:1 mixture, thereby reducing the homing index of
OVA+ MedLN DCs and increasing the homing index generated
by OVA+ ILN DCs.
Statistical Analysis
Statistical significance was calculated with GraphPad Prism (CA,
USA) using either an ANOVA with a Tukey post-test, two-
tailed unpaired t-tests with Holm-Sidak multiple comparison
correction and alpha of 0.05, two-tailed ratio-paired t-test with
95% CI, single sample t-tests with 0.05 alpha significance and
expected values of either 1 (for ratio comparisons) or 100 (for
percentage response comparisons), or two-way ANOVA with
Tukey post-tests, depending on the number of groups and type
of comparison, as indicated in the legends. Error bars in graphs
show the S.D. when comparing groups of individual mouse data
points, or alternatively the S.E.M. when data points represent
pooled data from independent experiments.
RESULTS
Higher Proportions of Ag+ dLN cDC1 and
cDC2 and Lung Homing T Cell Responses
Are Elicited by Intranasal Compared to
Intramuscular Immunization
We initially characterized the general DC response in dLNs
24 h post i.n. or i.m. immunization with fluorescent ovalbumin
protein antigen (OVA Ag) and Poly(I:C). Based on CD11b
and CD103 expression, we detected three distinct conventional
DC subsets in the draining MedLN and ILN (Figures 1A–C):
CD11b+, CD103+, and double negative (DN) CD11b− CD103−
DCs. CD11b+ DCs comprised of similar proportions of total
DCs in both dLN sites, whereas the CD103+ subset represented
higher, and the DN subset represented lower frequencies in
the MedLN compared to the ILN (Figure 1B) of immunized
mice. This was in contrast to naïve mice, where all three major
DC subsets were present in both LN sites at equal proportions
at steady state (Figure S1A). Of the tested time-points, the
percentage of Ag+ cells was highest on day 1 and had waned
by day 2–3 depending on the subset and site (Figure S1B).
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FIGURE 1 | Intranasal immunization results in higher percentages of specific Ag+ DC subsets and increases lung-trafficking of CD4+ T cells. (A–F) Draining LN (dLN)
suspensions from mice immunized i.n. or i.m. with fluorescent Ag (OVA) and Poly(I:C) 24 h earlier were stained with specific Abs prior to flow cytometric analyses. (A)
Representative cytometry plots of the gating strategy for conventional DCs, based on (43). DCs were defined as viable (non-autofluorescent, B220−, singlets; not
shown), MHC-II+, CD11c+, CD64low/int. DC subsets were based on CD11b, CD103, and Ag (OVA) expression. (B) Shows the percentage of DC subsets from total
conventional DCs, (C) the percentage of OVA+ cells within DC subsets and (D) the percentage of OVA+ DC subsets as a percentage of total live dLN cells. (B–D)
Show 6 pooled experiments with 6–12 mice per route per experiment. (E) Representative histograms of the OVA+ signal in selected DC subsets and an MHC-II−
control cell subset. (F) Shows the MFIOVA of the indicated DC subsets; 19 experiments pooled, 3–12 mice per route per experiment. (G–J) Purified naïve CD4
+
OVA-specific (OT-II) T cells were transferred into naive CD45.1− BL6 mice prior to i.m. or i.n. immunization with OVA/Poly(I:C). Ten days later, in vivo staining of
vascular leukocytes was performed immediately before removing the lungs to stain CD45.1+ OT-II cells. (G) Shows the gating strategy for representative mice from
one experiment, to identify OT-II cells in the lung parenchyma (CD45−) or vasculature (CD45+), after gating SSClow CD4+ T cells (singlet, viability, and CD3+ gates
not shown). OT-II cells in the indicated lung compartments are shown as (H) total numbers or (I) as percentages of total CD4+ cells or (J) total OT-II cells in the lung,
with individual mice (N = 8–10), pooled from two or more independent experiments. Statistical significance was calculated using an ANOVA when comparing three or
more groups, or a t-test for two groups, with SEM bars shown for pooled averages of multiple experiments, or SD bars for pooled individual mouse data, as detailed
in the Materials and Methods. P > 0.05; “ns,” not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001.
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There were higher percentages of Ag+ CD11b+ and CD103+
DCs in the MedLN compared to the ILN (Figure 1C), however
because of the differing total numbers of DC subsets per ILN
and MedLN, the absolute number of OVA+ CD11b+ DCs
was similar between sites, and the absolute number of OVA+
CD103+ DCs was higher in the MedLN (Figures S1C,D). OVA+
DCs comprised of more than 2.5% of all three DC subsets,
except for the DN DC subset in the MedLN (Figure 1C). Given
the low number per MedLN (Figures S1C,D) and very low
percentage of Ag+ DN MedLN DCs (Figure 1C), this subset
was not investigated further. Notably, the overall density of
Ag+ DCs was higher in the MedLN compared to the ILN
(Figure 1D). Additionally, themean fluorescence intensity (MFI)
of Ag in Ag+ cells appeared higher in CD11b+ compared to
CD103+ DCs (Figures 1E,F), regardless of which LN site was
compared. There were no differences in Ag MFI between the
same DC subsets from ILN and MedLN (CD11b+ DC; CD103+
DC; Figure 1F).
Next, we investigated whether i.n. immunization elicits an
enhanced lung-trafficking CD4+ T cell response. Naïve (CD44−)
OVA-specific CD4+ T cells (OT-II) were adoptively transferred
into recipient naïve BL6 mice, which were then immunized i.n.
or i.m. with OVA/Poly(I:C). Post-transfer of OT-II cells, and
immediately prior to sacrifice, in vivo intravenous staining (42)
was used to discriminate parenchymal and vascular lung T cell
localization (Figure 1G). Significantly higher numbers of OT-II
cells were detected in the lung after i.n. immunization compared
to after i.m. immunization (Figure 1H). Airway priming of T
cells also resulted in an enrichment of OT-II cells in the lung
parenchyma as a percentage of total CD4+ T cells (Figure 1I),
or as a percentage of OVA-specific T cells (Figure 1J). Globally,
these results confirmed that i.n. immunization increases the
homing of CD4+ T cells into the lung interstitium compared to
i.m. immunization.
Increased Priming and Induction of
Lung-Homing Markers on CD4+ T Cells by
in vivo-Activated MedLN DCs Compared to
ILN DCs
Because the two routes of immunization elicited different lung-
homing T cell responses, we then directly compared the ability
of MedLN and ILN DCs to prime naïve T cells. CD11b+ and
CD103+ DC subsets harvested from the dLNs of OVA/Poly(I:C)-
immunized mice were cytometry-sorted and co-cultured with
purified OT-II cells in the absence of exogenous cytokines or
antigens. T cell activation, as measured by CD44 expression
(44) (Figure 2A) of gated OT-II cells (Figure S2A) was detected
at early time-points (day 1) and continued increasing at day
3 (Figure S2A and Figure 2B). The most potent activating
DCs were Ag+ MedLN CD11b+ DCs, which on average
elicited 55% CD44+ OT-II cells (Figure 2B) and had a T cell
stimulation index of 260 times that of the media-only stimulated
OT-II cells (Figure 2C). This level of T cell activation was
significantly higher compared to Ag+ CD11b+ DCs from the ILN
(Figure 2B). All Ag− DC subsets elicited minimal (1–8%) T cell
activation (Figure 2B), demonstrating that Ag was required to
elicit robust T cell activation. Antigen-positive CD103+ MedLN
DCs primed significantly higher numbers (Figure 2C) of T
cells compared to their equivalent counterparts from the ILN.
However, OT-II priming mediated by CD103+ (cDC1) DCs was
on average 10.15 times lower than priming by CD11b+ DCs,
confirming the observations that show specialization of cDC1
and cDC2 subsets in priming CD8+ and CD4+ T cell responses,
respectively (45–47). We therefore focused on CD11b+ DCs to
further evaluate CD4+ T cell priming by MedLN vs. ILN DCs.
We assayed for changes in the expression of 9 airway-
associated chemokine receptors and integrins, as well as cell
activation or lineage markers on the surface of OT-II CD4+ T
cells after co-culture with total CD11b+ DCs from the MedLN or
ILN of immunized mice (Figure 2D and Figure S2B). This initial
screening demonstrated that MedLN-derived DCs induced high
percentages of T cells that expressed CD69, α4β7, CXCR3, and
CD49a, and reduced the expression of CD62L more visibly than
ILN DCs (Figure 2D). Furthermore, Ag+ MedLN DCs induced
higher percentages (Figure 2E) and numbers (Figure 2F) of lung
homing CXCR3+ CD49a+ OT-II cells, including at multiple
time-points of the co-culture (Figure 2G; day 1, and Figure S2C;
day 3). Ag+ MedLN-derived CD11b+ DCs could selectively
enhance the induction of lung homing OT-II cells (Figure 2G;
far right graph), as determined by first gating on CD44+ cells to
normalize for the variation between the overall T cell priming
capacity of OVA+ ILN and MedLN DCs (Figure 2A). We were
unable to detect CCR4, previously described in T cell co-cultures
with airway-DCs (34) or other selected molecules that have
been implicated with lung-homing (CXCR4, CXCR5, CXCR6;
Figure S2B) (6, 34, 48), including in co-cultures of up to 5
days (data not shown). Increased percentages of endogenous
(polyclonal) CXCR3+ CD49a+ double positive cells were also
observed at higher frequencies directly ex vivo in the CD44+
CD4+ T cell compartment of the MedLNs of i.n.-immunized
BL6 mice compared to the ILN of i.m. immunized mice
(Figures S2D,E).
MedLN CD11b+ DCs Induce CXCR3 and
CD49a Expression on CD4+ T Cells That
Home to the Lung Parenchyma
DC-induction of in vivo T cell homing capacity was investigated
by using sorted CD11b+ DCs to prime OT-II cells, which were
then transferred into naïve lymphocyte-deficient (RAG2−/−)
recipient mice. As the overall level of T cell activation by
ILN DCs was lower, we additionally used OT-II peptide
pulsing of Ag− DCs as a comparison to the standard in-
vivo loaded Ag+ DC co-culture, which approximately equalized
in vitro T cell activation by DCs from either the ILN
or MedLN (Figure 3A). Prior to transfer, the T cells from
MedLN and ILN DC co-cultures were differentially stained to
allow discrimination of their co-culture origin in vivo. Post-
transfer, and immediately prior to sacrifice, additional staining
was performed to determine the localization of OT-II cells
within the lung (Figure 3B). MedLN-derived DCs imprinted
cell-homing capabilities that resulted in greater percentages
(Figure 3C; P < 0.001 for all MedLN and ILN comparisons)
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FIGURE 2 | In vivo-activated DCs in the lung- and muscle-draining LNs differentially prime CD4+ T cells in terms of speed, magnitude, and induction of lung homing
molecules. (A–G) Mice were immunized by the i.n. or i.m. route with fluorescent OVA and Poly(I:C). After 24 h, the indicated DC subsets (5,000 cells per subset) were
sorted from dLN suspensions and co-cultured with 100,000 naive OT-II CD4+ T cells for 1–3 days in the absence of exogenous cytokines or antigen. (A)
Representative flow cytometry histograms of CD44 expression of gated OT-II cells after 3 days of DC co-culture. (B) The percentage of CD44+ OT-II cells after 3 days
of co-culture with either OVA+ or OVA− CD11b+ or CD103+ DC subsets from the draining ILN or MedLN of immunized mice. (C) OVA+ DC subset priming of OT-II
cells, expressed as a stimulation index that represents the fold-change in OT-II numbers per well, compared to the media control. (D) Representative histograms of
OT-II CD4+ T cell phenotype after 3 days of DC co-culture. (E–G) OVA+ CD11b+ DCs were sorted from the dLNs of i.m. or i.n. immunized mice and co-cultured with
naïve OT-II cells for 3 days or as indicated. (E) Representative flow cytometry contour plots of CD49a and CXCR3 expression of CD44+ CD4+ T cells after DC
co-culture with OT-II cells on day 2 of in vitro activation. (F) OVA+ CD11b+ DC subset induction of lung homing molecules CXCR3 and CD49a on OT-II cells,
expressed as a stimulation index, which represents the fold-change in numbers per well, compared to the media control OT-II cell culture. (G) The percentage of gated
OT-II cells expressing the indicated lung-homing molecules after 1 or 2 days of DC co-culture. In (B,C,F,G), points represent the mean response from individual
experiments with SEM bars. An ANOVA was used in (B,G), and a two-tailed ratio t-test was used in (C,F), as described in the Materials and Methods. P > 0.05; “ns,”
not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
and numbers (Figure 3D; OVA+ DCs) of activated OT-II in
the lung parenchyma in vivo (Figure 3D; OVA-pulsed DCs),
even after normalizing for the difference in CD44+ cells in
the 1:1 mixture of live co-cultured OT-II cells (see Figure 3A)
that were then adoptively transferred. In contrast, ILN DC-
primed OT-II showed a strong homing preference for the
spleen, equivalent to over 10-fold in terms of absolute numbers
(Figure 3D). Approximately the same number of MedLN and
ILN DC primed (CD44+) OT-II cells were detected in the lung
vasculature post-transfer (Figure 3D; p > 0.05). A relatively high
number of MedLN-DC primed OT-II cells were unaccounted
for, suggesting either cell death, or homing to other sites,
including the mucosa. The latter is plausible considering that the
gut-homing molecule α4β7 was induced by intranasal-route DCs
in our study (Figure 2D) and previously by other experimental
airway-delivered vaccines (49–51), in addition to other known
redundancies in tissue-trafficking molecule specificity (52, 53).
Too few of the in vitro activated OT-II cells were detected
in the LNs post-transfer to perform accurate quantitative or
qualitative analyses.
The lung parenchyma-homing advantage mediated by
MedLN CD11b+ DCs was further supported by an analysis of
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FIGURE 3 | In vivo lung parenchyma-homing advantage of OT-II cells primed by MedLN DCs. OT-II cells were co-cultured for 3 days with OVA+ or OT-II
peptide-pulsed OVA− CD11b+ DCs from the draining ILN or MedLN of immunized mice. (A) Co-cultured OT-II cells were stained for flow cytometric analysis to
determine CD44 expression, one representative experiment shown. Cells from MedLN or ILN DC co-cultures were labeled with high or low concentrations of CFSE,
respectively, and mixed at a 1:1 ratio of live cells before i.v. injection into T cell deficient Rag2−/− mice (n = 6 per DC co-culture type). The following day, mice were
injected i.v. with labeled anti-CD45 Ab prior to sacrifice to distinguish parenchymal vs. vascular lung leukocytes, and organs were harvested for flow cytometric
analysis. (B) Flow cytometry contour plot gating strategy using 6 concatenated samples to distinguish the lung compartment and cell-culture origin (ILN or MedLN DC
primed) of the transferred OT-II cells recovered ex vivo. (C) The percentage of activated OT-II from DC co-cultures detected in different lung compartments. (D) The
tissue homing index, expressed as a ratio of the number of MedLN to ILN DC-primed (CD44+) OT-II cells detected in different tissues after normalization, see
Materials and Methods. (C,D) Data represents individual mice (n = 3–6) from one of two independent experiments. (E,F) Phenotype of CD44+ OT-II cells detected in
recipient mice lung compartments, shown as (E) concatenated flow cytometry contour plots, or (F) the expression intensity of the indicated lung homing markers,
from six mice representing one of two independent experiments. Statistical analysis comprised of a one way ANOVA in (C,F), single sample t-test in (D), and SD error
bars, as detailed in the Materials and Methods. P > 0.05; “ns,” not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
the phenotype of activated (CD44+) OT-II cells post in vivo
transfer (Figures 3E,F; Figure S3A). High percentages ofMedLN
DC-primed OT-II cells co-expressed the activation and tissue
retention marker CD69 with either CD49a or CXCR3, whereas
CD69 was expressed mainly in the absence of these lung-homing
markers in ILN DC-primed OT-II cells (Figure 3E). Over 75%
of all OT-II cells activated by MedLN DC, which were isolated
from the lung parenchyma expressed CD69 (54, 55) in addition
to either CD49a or CXCR3, whereas <10% of ILN DC-induced
parenchymal OT-II cells were double-positive for combinations
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FIGURE 4 | Phenotypic differences between MedLN and ILN CD11b+ DCs. Draining LNs of male or female mice, after i.n. or i.m. immunization 24 h earlier with
fluorescent OVA and Poly(I:C), stained for flow cytometric analysis. (A) Shows histograms of CD86 expression, (B) shows CD86 MFI of OVA+ or OVA− CD11b+ DCs,
and (C) shows the MFI of various markers in CD11b+ DCs from the indicated LNs. (A–C) Show data from one of three similar experiments (D) shows the ratio of
gMFI for the indicated markers from MedLN to ILN Ag+ CD11b+ DCs, calculated after normalizing each sample with isotype or “fluorescence minus one” Ab staining
controls. The dotted line indicates an arbitrary 3-fold higher or lower ratios of expression, individual points represent experimental repeats, pooling LNs from 3 to 12
mice per immunization route, with p-values calculated using a single-sample t-test (0.05 alpha, expected MFI ratio of 1). (E) Co-expression of the indicated surface
markers in the indicated cell subsets from one of three similar experiments. (F) Shows a t-SNE analysis of an equal number of OVA+ CD11b+ cDCs from the dLNs of
i.n. or i.m. immunized mice as described in the Materials and Methods. t-SNE data was used to generate (G) pie graphs showing the percentage of cells in each
t-SNE gate, relative to total OVA+ CD11b+ cDCs from the same LN, and (H) column graphs show the cell surface gMFI of the indicated markers in each of the t-SNE
gates using combined ILN and MedLN data. t-SNE data is representative of three independent experiments. P > 0.05; “ns,” not significant; *P < 0.05; **P < 0.01;
***P < 0.001.
of these markers (Figure 3E). MFI analysis demonstrated that
both CD49a and CXCR3 were expressed on average at higher
levels in MedLN DC-primed OT-II cells found in both the lung
interstitium and parenchyma compared to OT-II primed by ILN
DCs (Figure 3F), and additionally in the vasculature for CXCR4
(Figure S3B). CXCR3 expression of MedLN DC-activated
OT-II cells was significantly higher in T cells found in the
lung compared to the spleen, with a similar trend for CD49a
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(Figure 3F). This suggests that CXCR3 may be a more specific
lung-homing molecule or is upregulated to a higher degree
compared to CD49a in our model.
Identification of Site-Specific Differences
in dLN CD11b+ DC Surface Markers,
Including Co-expression of High Levels of
Multiple Co-stimulatory and Activation
Markers on MedLN DCs
Data showing that MedLN DCs were superior to ILN DCs
at activating CXCR3+ CD49a+ CD4+ T cells prompted a
detailed analysis of DC phenotype to gain insight about
the imprinting mechanisms at play during T cell priming.
We initially investigated the expression of CD86, a well-
characterized T cell co-stimulatory molecule which is often
used to indicate stimulatory capacity or the activation status
of antigen-presenting cells. At 24 h post-immunization, CD86
was found at higher levels on the surface of Ag+ CD11b+ DCs
from the MedLN compared to the ILN (Figures 4A,B). We
excluded the possibility that MFI differences in surface molecule
expression were due to cell size using image-based cytometry
(Figure S4A), or due to kinetics by harvesting the dLNs at
later time points post-immunization (Figures S4B,C). Although
baseline levels of CD86 were slightly higher in ILN-derived DCs
(Figures S4B,C; naïve mice), much higher CD86 expression was
consistently detected in Ag+ MedLN-derived DCs at day 1 post-
immunization, and required several days to return to baseline
levels (Figures S4B,C).
Recognizing that the expression level of a key co-stimulatory
molecule was affected by the anatomical location of DCs,
we then compared the expression of 254 additional leukocyte
markers on the surface of Ag+ CD11b+ DCs from the ILN
and MedLN at day 1 post-immunization. Several markers
were expressed with a >3-fold difference on the surface
of Ag+ CD11b+ DCs in the draining MedLNs vs. ILNs
of OVA/Poly(I:C)-immunized mice. These included F4/80,
CD273 (PD-L2), CD157, podoplanin (PDPN), GL7, and CD24
(Figure 4C). This result was reproduced upon immunization
with adjuvants targeting distinct TLRs, namely CpG 1826 (TLR9)
and LPS (TLR4) (Figure S4D), which suggests that the molecular
surface signature of DCs from different sites is a generalized
phenomenon after adjuvanted OVA immunization. The majority
of surface markers were not differentially expressed on the
surface of ILN and MedLN DCs (Table S1), including co-
stimulatory and antigen presenting molecules, such as CD40,
MHC-I, MHC-II (Figure 4D), and TGF-β (Figure S4E)—which
has previously been reported to mediate imprinting of lung-
homing CD103+ CD8+ T cells by CD1c+ human DCs (24). A
few markers were statistically different between MedLN and ILN
Ag+ DCs, however, with a lowermagnitude of difference between
1.5- and 3-fold (Figure 4D). The majority of differentially
expressed markers between dLN sites are well-characterized for
their involvement in co-stimulation (CD80, CD86, “heat stable
antigen” CD24) or co-inhibition (F4/80, CD273, CD80) of T cells,
adhesion and immunological synapses (CD44, CD54/ICAM-
1, CD11a, CD11b, CD11c), or are currently used as leukocyte
activation markers (GL7, CD44, PDPN); Table 1 (31, 44, 56–60).
Interestingly, differential expression of many of these markers
was detected between MedLN and ILN DCs even prior to
immunization (Figure S4B).
The three markers found at more than 3-fold higher levels on
MedLN DCs (CD24, HSA; GL7; and PDPN), were investigated
in more detail. By simultaneously evaluating their surface
expression, in addition to CD86, we aimed to evaluate whether
these markers were co-expressed on the same cell, or alternatively
on mutually exclusive cell subsets. Bivariate dot plots allowed
the investigation of pairs of markers, which demonstrated a high
level of co-expression at the single cell level (Figure 4E) and
highlighted the existence of some unique cell distributions, for
example MedLN DCs that co-expressed very high levels of both
GL7 and CD24. To further stratify the CD11b+ DC compartment
based on the more highly-expressedMedLNDC surface markers,
we employed the t-distributed stochastic neighbor embedding
(t-SNE) dimensionality reduction algorithm. Visualization of 4-
dimensional data on a 2D t-SNE plot assisted in the identification
of a DC subphenotype that simultaneously expressed high levels
of CD24, CD86, GL7, and PDPN (Figures 4F–H). This cell sub-
phenotype (labeled G9, Figures 4F–H), represented over 34%
of Ag+ CD11b+ DCs in the MedLN, and under 5% of Ag+
CD11b+ DCs in the ILN (Figure 4G). TheMFI analysis of each of
the 9 gated sub-phenotypes (G1–G9, histograms in Figure S4F)
revealed that the most abundant Ag+ CD11b+ DCs in the ILN
(G4 and G5) expressed low levels of CD24 and intermediate
TABLE 1 | Summary of differentially-expressed surface markers between MedLN and ILN Ag+ CD11b+ DCs.
DC surface molecule(s) LN with increased expression Molecule function
CD24 (HSA) MedLN T cell co-stimulation and cell migration
CD80, CD86 MedLN T cell co-stimulation or co-inhibtion
CD11a, CD11b MedLN Adhesion
PDPN (podoplanin) MedLN Lymphatics/LN trafficking, IFN response
F4/80 ILN Adhesion, Treg induction
CD273 (PD-L2) ILN T cell co-inhibitory molecule
CD38, CD157 ILN Calcium and NAD regulation
CD11c, CD44, CD54 (ICAM-1) ILN Adhesion, migration, immunological synapse
MedLN, mediastinal lymph node; ILN, inguinal lymph node; NAD, nicotinamide adenine dinucleotide; IFN, interferon; Treg, regulatory T cell.
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levels of CD86 co-stimulatory molecules, and less abundant sub-
phenotypes (∼10% of total Ag+ cells, e.g., G3 and G6) did not
simultaneously express moderate or high levels of more than
one type of co-stimulatory (CD86 or CD24) or activation marker
(PDPN or GL7).
Lung-Homing CD4+ T Cells Are Efficiently
Induced by Ag+ CD24+ CD11b+ DCs,
Which Are Enriched in the MedLN
Compared to the ILN
Various approaches were used to elucidate the contribution to
T cell priming and induction of lung homing molecules that
was mediated by surface markers expressed at more than 3-
fold higher levels on MedLN than ILN DCs. Firstly, specific
Ab blockade was performed in a co-culture of in vivo-activated
cytometry-sorted CD11b+ DCs and OT-II T cells. A significant
reduction of the general activation of OT-II cells (Figure 5A) was
detected after blockade of CD24, GL7, and using the anti-CD86
mAb control, but not anti-PDPN mAb. When the proportion
of lung-homing CD49a+ CXCR3+ OT-II cells was analyzed
(Figure S5A), there was a trend for CD24, GL7, and CD86
blockade to specifically suppress 30–40% of the induction of
these cells.
Knowing that from the various surface markers tested
on dLN CD11b+ DCs post-immunization, CD24 showed the
highest average expression difference between the two LN sites
(Figure 4D), we then delineated and characterized the CD24+
and CD24− subsets in terms of their CD4+ T cell stimulation
activity. A Principal Component Analysis that compared DCs
from both LNs in terms of their combined expression of CD24,
CD86, GL7, and PDPN (Figure S5B) also demonstrated that
CD24 was a major contributing factor to the variation between
MedLN and ILN DCs (PC1 loading matrix in Figure S4F).
Therefore, CD24 appears to represent a good candidate to
discriminate DCs elicited by i.n. vs. i.m. immunization, and a
potential biomarker, in addition to CD86 and GL7, for DCs with
high potency in terms of CD4+ T cell activation.
In the in vitro co-culture model of naïve OT-II with sorted
Ag+ DCs from immunized mice, CD24+ CD11b+ DCs initiated
higher levels of T cell stimulation (Figure 5B) compared to
the CD24− DC subset from the same dLN. There was no
difference in the ability of CD24+ DCs from the draining
MedLN and ILN for overall (CD44+) CD4+ T cell activation
(Figures 5B,C). Using sorted DC subsets provided clearer results
than the Ab blockade, by demonstrating that CD24+ CD11b+
DCs had an enhanced ability to selectively induce statistically
greater numbers (Figure 5C), and a trend for higher percentages
(Figure S5C), of lung-homing CD4+ T cells. Interestingly,
CD24+ CD11b+ DCs from the MLN and ILN showed an
equal capacity to prime T cells with a lung-homing phenotype
(Figure 5C). While CD24+ and CD24− CD11b+ DCs were
sorted in these experiments, it is likely that the high co-
expression of other surface molecules, such as CD86 and GL7
(Figures 4E,H) or possibly undefined secretory factors, also
contribute to the enhanced induction of CD49a+ CXCR3+ OT-II
cells by CD24+ DCs.
In addition to the use of lineage markers, such as CD4 and
CD8, LN-resident DCs are often distinguished by low MHC-II
and CCR7 expression, compared to migratory DC which express
higher levels of MHC-II and CCR7, notably upon maturation
(61–64). Therefore, to predict the anatomical origin of the
potent CD24+ CD11b+ DCs, we evaluated their expression of
CD4, MHC-II, and CCR7 after OVA immunization with either
Poly(I:C) or CpG. Most CD24+ cDC were CD4− (Figure S6A)
and expressed higher CCR7 and MHC-II (Figures S6B,C),
suggesting that this subset is not a cDC2 LN resident population
and is likely to have migrated from the lung.
Having established that CD24+ DCs are highly potent
activators of CD4+ T cells, including lung-homing T cells, we
evaluated the abundance of this subset ex vivo in the dLNs
of immunized mice. Highly potent (OVA+ CD24+ CD11b+)
DCs represented much higher proportions of total MedLN DCs
compared to ILN DCs (Figure 6A; P = 0.0003). Furthermore,
the majority (over 80%) of Ag+ CD11b+ DCs were CD24+ in
the MedLN, whereas <30% were CD24+ in the ILN (Figure 6B),
which directly corresponds to the overall CD24 MFI differences
observed in the DC surface molecule screen (Figure 4D). The
increased percentages of CD24+ DCs in the draining MedLN
was not a TLR-targeting specific phenomenon because CpG and
LPS also induced a similar distribution of Ag+ cells in the dLNs
(Figure S6D). More importantly, analysis of the percentage of
potent Ag+ CD24+ DCs of total live LN cells revealed a much
higher density of this cell subset in the MedLN (Figure 6C),
higher total numbers of Ag+ CD24+ CD11b+ per MedLN
(Figure 6D), and higher expression of CD24 per cell (Figure 6E).
Therefore, because the percentage of CD4+ T cells in both the
MedLN and ILN is equivalent (Figure S6E), the ratio of potent
CD24+ DCs per CD4+ T cell is much higher in the MedLN—
which is likely to be a key contributing factor to the enhanced
output of lung-homing T cells in vivo after i.n. compared to
i.m. immunization.
DISCUSSION
Factors that shape the trafficking potential of T cells include
tissue-specific cues, T cell receptor stimulation strength, as well
as inflammation in secondary lymphoid organs and peripheral
tissues (65). More specifically, soluble factors including vitamins
and IL-12 are known to be involved in DC-mediated imprinting
of gut and skin-homing molecules on T cells (21–23, 66).
Apart from one report detailing how DC surface-bound TGF-
β promotes the accumulation of CD8+ T cells in the lung
(43), there is limited evidence of DC surface molecule-mediated
induction of tissue homing molecules on T cells. Previous
reports have shown that TCR signal strength, which relies on
immunological synapse interactions at the cell surface, can skew
the outcomes of T cell priming (67), for example, the balance
between of effector vs. memory lymphocyte differentiation (57,
68). In the current study, surface molecules of in vivo-matured
DCs were shown to be important mediators that control the
quantitative output of the T cell response, as well as imprint
lung-homing molecules on CD4+ T cells.
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FIGURE 5 | Role of specific DC surface molecules and subsets in the activation of T cells and the induction of lung-trafficking molecules. (A) Draining MedLN OVA+
CD11b+ DCs from mice immunized 24 h earlier, were incubated with isotype control Abs or the indicated blocking mAbs before co-culture and evaluation of %
CD44+ OT-II cells. Values are relative to the isotype control reference (100%) for 3–5 independent experiments, showing SEM error bars and compared using a one
sample t-test with expected value of 100%. In (B,C), 5000 OVA+ CD24+ or CD24− DCs were isolated from the dLNs of i.n. or i.m.-immunized mice and co-cultured
with 100,000 naïve OT-II cells. The stimulation index refers to a fold-increase of the numbers of (B) CD44+, or (C) CD49+ CXCR3+ CD44+ OT-II cells compared to
the media-only control. (B,C) Show 4–5 independent experiment repeats with SEM error bars, and statistical differences were calculated with a ratio paired t-test.
P > 0.05; “ns,” not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
FIGURE 6 | Intranasal immunization elicits higher frequencies and numbers of DCs with potent T cell priming capacity. (A–E) Conventional flow cytometric analysis of
DCs from the dLN of mice immunized 1 day earlier by the i.n. or i.m. route with fluorescent OVA/Poly(I:C). (A) The percentage of OVA+ CD24+ CD11b+ DCs of total
DCs, (B) the percentage of CD24+ cells of OVA+ CD11b+ DCs, (C) the percentage of OVA+ CD24+ CD11b+ DCs of total live cells. (D) Shows the number of
CD24+ or CD24− OVA+ CD11b+ DCs per dLN (E) shows the number of CD24+ or CD24− OVA+ CD11b+ DCs per dLN. (E) Shows CD24 gMFI of OVA+ CD24+
CD11b+ DCs. (A–E) Show 4–7 independent experiment repeats with SEM error bars, and a paired t-test statistical comparison. **P < 0.01; ****P < 0.0001.
Priming the immune response via different routes in vivo
resulted in different proportions of Ag-loaded and mature DC
subsets in the corresponding dLNs. Importantly, we detected
several site-specific differences in dLN DCs. Lung-associated
LN DCs of immunized mice expressed higher levels of known
costimulatory molecules than otherwise similar DC subsets in
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muscle-draining LNs. MedLN DCs were superior at overall
priming of CD4+ T cells in terms of kinetics and output of
CD44+ effectors, and notably induced rapid expression of lung-
homing markers CXCR3 and CD49a. Rapid induction of tissue
homing markers has been reported previously (69). This could
therefore represent a means of deploying T cells to the mucosa
within as little as 2 days post-priming, which is supported by
ex vivo results detecting CD49a CXCR3 double-positive Ag-
specific T cells in the dLNs of i.n. immunized mice at very early
time-points post-immunization (Figure S2E).
A combination of in vitro and ex vivo data was used to
infer the in vivo contribution of DCs to the induction of lung-
homing of T cells. Ex vivo screening demonstrated that one
of the most prominent differences between MedLN and ILN-
derived CD11b+ DCs early after immunization was the level of
CD24 expression. CD24 is a polyfunctional and widely-expressed
molecule which is implicated in cell adhesion (70, 71), apoptosis
and proliferation (72, 73). It also distinguishes Langerhans cells
from dermal DCs (74), and has been used extensively as a
lineage marker for B cell subsets (75, 76). The costimulatory
property of CD24, when expressed by antigen presenting cells,
is well-described (57, 73, 77), and one report details its specific
contribution to inducing mucosal T cells and importance in DC
subset classification (78). Subsequently, using sorted CD24+ and
CD24− CD11b+ DC subsets, we demonstrated that CD24+ DCs
had an enhanced ability to prime CD4+ T cells in vitro, including
those with a lung-homing phenotype. We then returned to
quantify this potent DC subset ex vivo, showing that CD24+
CD11b+ DCs are found at much higher proportions in the
draining LNs of i.n. compared to i.m.-immunized mice.
Recently, tissue-specific differences in surface molecule
expression within major DC subsets have been observed at steady
state in human tissues (79). Higher proportions of mature cDCs
were detected in the draining LNs of human lung, and expressed
relatively high levels of CD26 (79), a known T cell costimulatory
molecule (80), compared to cDCs that drained other organs.
The present study supports these findings by demonstrating the
functional relevance of differential molecule expression patterns
between anatomical sites. Namely, we show that DC surface
marker signatures generated by different routes of immune
priming result in quantitatively and qualitatively different CD4+
T cell responses.
Similarly to CD24, Ag+ CD11b+ MedLN DCs express >3-
fold more PDPN and GL7, and to a lesser extent (1.5-fold)
CD80 and CD86 than those from the ILN. Our results implicate
CD24, CD86, and GL7 as DC surface molecules that contribute
to T cell priming. GL7 has been used as an activation marker
of lymphocytes (56), although to our knowledge its ability to
function as a costimulatory molecule when expressed by DCs
has not been described. Despite higher expression of PDPN in
MedLN-derived DCs, this molecule did not appear to contribute
to T cell priming, but was co-expressed with other costimulatory
markers and therefore represents a surrogate marker of potent
CD4+ T cell-activating DCs. In contrast, muscle LN-associated
DCs expressed higher CD273 (PD-L2) and F4/80 and resulted
in lower T cell responses compared to airway LN DCs, which
corresponds to the known role of these markers in suppressing
anti-microbial and anti-tumor T cell responses, or increasing
regulatory T cell activity (81, 82).
Our results also demonstrate that CD24+ CD11b+ DCs are
likely to be migratory (Figures S6A–C), which supports studies
demonstrating that non-lymphoid tissue-resident DCs are potent
inductors of T cell tissue-homing molecules for various tissues
(23, 83–85). Furthermore, CD11b+ CD24+ CD64low murine
DCs have previously been shown to be functional homologs of
human CD1c+ DCs (78), however the expression of CD24 on
human DCs is not well-characterized at present. Nevertheless,
the cDC2 subset constitutes the majority of conventional DC in
all human tissues (79). cDC2 therefore represent an important
cell subset to characterize fully, and a putative cellular target for
vaccines and immunotherapies.
The immunization model used in the present study included
the administration of soluble protein and TLR agonists, such
as Poly(I:C), LPS, and CpG, via either the intranasal or
intramuscular route. These routes differ greatly in terms of
cellular and lymphatic structural features, as well as the
microbiota and soluble microenvironment properties of the two
sites, which could all contribute to the initiation of disparate
immune responses after i.n. vs. i.m. immunization. Qualitative
or quantitative differences in immune responses could also arise
due to site-specific differences in TLR-mediated inflammation, or
during the capture, drainage, and processing of Ag. Whether and
to what extent these general features of the two immunization
sites contribute to DC phenotype and subset density, or affect
the imprinting of mucosal trafficking molecules on T cells
independently to DCs, remains to be determined. We speculate
that the different overall T cell priming capacity of ILN and
MedLN-derived DCs is additive, i.e., relies on a combination
of multiple co-stimulatory signals, both surface and secretory,
as reviewed elsewhere (29, 86). Additional experiments are
therefore needed to delineate the involvement of secretory factors
and additional transcriptomic networks that are differentially
regulated by DCs from different sites. As T cell-imprinting is
also known to be affected by soluble factors produced in mucosal
tissues (53), which can drain directly to dLNs via conduits
(87), future research could test the effects of respiratory tract-
enriched soluble factors, or CD24+ DC subset specific factors,
for their contribution to the induction of T cell tissue homing
receptors. Nevertheless, because the current study attempted
to unravel in vivo mechanisms that modulate lung-homing T
cell responses, we considered the inherent biases related to Ag
delivery at different sites as necessary for the discovery of DC-
related phenomena and processes that play a role in vivo.
Previous studies have determined that CCR4 (34) is
upregulated on T cells primed by airway LN-derived DCs, which
translates to increased lung-homing potential of T cells. T cell
surface CCR4 upregulation was not detected in our model after
DC co-culture (Figure S2B). This possibly stems from large
differences in the study protocols regarding how the DCs were
activated. The majority of experiments performed by Mikhak
et al. included DCs that were Ag-loaded and activated in vitro,
in contrast to the in vivo immunization used in the present study
with a highly Th1-polarizing adjuvant (88). Except for a few
isolated reports (89) and the present study, most previous studies
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have employed DCs that were loaded with Ag ex vivo, in vitro-
generated, or Flt3L-expanded, often in the absence of stimuli
to fully mature DCs, which could introduce artifacts, such as a
skew toward regulatory, Th2, or anergic T cell responses. We
therefore speculate that multiple different chemokine receptors,
including CCR4, and those described in the present study, can all
contribute to T cell homing to the lung in different contexts. This
is supported by findings in the allergy and asthma research fields
that demonstrate the involvement of CCR4 and other chemokine
receptors in recruiting Th2-like cells to the lung (90, 91). In
contrast, immunizations (18, 92, 93) or infections (94, 95) that
induce Th1 or Th17-polarizing inflammation are known to prime
lung-homing CD4+ T cells that express CCR6 and CXCR3.
Functional differences in cDC1 and cDC2 stem from their
unique differentiation programs, and have been shown to
greatly influence Ag-processing and presentation outcomes (96).
CD103+ DCs are known to express very high levels of CD24 (68).
These pulmonary CD103+ (CD24high) DCs are potent inducers
of mucosal-homing CD8+ T cells (68), as well as mediators of
IgA class-switch recombination (97). Placed in context with the
current study, CD11b+ cDC2 expressed several fold less CD24
than their CD103+ cDC1 counterparts from the same tissue
(data not shown), however, these CD24+ CD11b+ DCs provided
completely sufficient co-stimulatory signals to induce a robust
CD4+ T cell response including augmented numbers of cells
with lung-homing capacity. The CD24 pathway could therefore
be potentially targeted by immunostimulatory compounds with
the aim of improving both CD4+ and CD8+ mucosal-homing T
cell responses.
Lymphocyte trafficking to the desired tissue is thought of as a
critical process in successful vaccination and immunotherapeutic
strategies. One example of this comes from the pneumococcal
field, where different immune stimuli, including infection
and mucosal vaccination against respiratory pathogens
in humans, have been shown to modulate tissue-homing
receptor (α4β7 and L-selectin) expression of B cells (98).
Here, our results link the density (Figures 1D, 6C) and
phenotype (Figure 4E) of DCs in the respiratory tract LN
with CD4+ T cell responses of greater magnitude and
with greater lung-homing capacity (Figures 5B,C). As
we focused on lung parenchyma homing in our model,
future studies could be used to investigate whether the
induction of CXCR3 and CD49a also favor the trafficking
of T cells to other sites, including other mucosal tissues of
the conducting airways, which are often critical entry points
for pathogens.
Mucosal vaccination strategies are being investigated
intensively (99–101), and represent a method to prime
enhanced immune responses that protect the respiratory
(102–106), reproductive (107), and gastro-intestinal tracts
(108). However, mucosal approaches have undergone less
clinical development to date compared to the parenteral
route, possibly due to safety concerns about the intranasal
route (109). Nevertheless, understanding the mechanisms
that program T cell tissue-trafficking remains pertinent in
the fields of vaccinology and immunotherapy. The current
study and previous reports (34, 68, 97) put forward a
strong rationale to administer vaccines in such a way that
airway-resident DCs are loaded with Ag and matured.
This could be achieved using either i.n. immunization,
or alternatively direct intrapulmonary inhalation into the
lungs via the mouth (110)—to avoid nasal administration
of immune-stimulants within close proximity to the facial
nerve (111).
Furthermore, inducing robust mucosal immunity to improve
protection against respiratory pathogens might also be achieved
using standard needle-based vaccination. For example, the
development of next-generation parenteral adjuvants could aim
to enhance the proportion of potent CD24+ DCs in muscle-
draining LNs, or otherwise provide the costimulatory and
secretory molecule signatures that enhance mucosa-homing
CD4+ T cell responses. In fact, transcription factors, such as
IRF4 that are critical for the development of pulmonary CD24+
CD11b+ DCs have already been characterized (112). In addition
to enhancing lung-homing imprinting signals provided by DCs,
there are also existing methodologies to increase total numbers
of DCs that drain to the LN after parenteral immunization (113),
which could address the lower ratio of DCs to T cells we observed
in the muscle-draining LN.
To conclude, potent mucosal CD8+ T cell and humoral
responses have been achieved using systemic immunization
(114–116), which indicates the feasibility of improving parenteral
injection-based vaccine strategies. However, the mechanisms
involved have not been elucidated. Therefore, more in-depth
knowledge of the molecular switches and signatures that
influence T cell pulmonary-tract homing potential, which we
have begun to unravel in the present study, paves the road for the
rational design of novel and more effective immune prophylaxis.
DATA AVAILABILITY
The datasets for this manuscript are not publicly available
because this is the first study using a newly generated
dataset, and the data can be made publicly available after
publication. Requests to access the datasets should be directed
to david.pejoski@unige.ch.
ETHICS STATEMENT
Mice were bred or housed in pathogen-free animal facilities at
the University of Geneva in accordance with local guidelines.
Experiments were comprised of either all male or all female
cohorts at 6–8 weeks of age, and conducted in accordance
with the Geneva Veterinary Office Ethics Committee, and
European guidelines.
AUTHOR CONTRIBUTIONS
C-AS, DP, P-HL, PA, and DC designed the study. The
experiments were designed by DP and C-AS with input from
MV, FA, and MB. The experiments were performed and analyzed
by DP. The manuscript was written by DP and edited by C-AS,
P-HL, PA, DC, MV, FA, and MB.
Frontiers in Immunology | www.frontiersin.org 14 July 2019 | Volume 10 | Article 1650
Pejoski et al. DC Activation of Lung-Trafficking T Cells
FUNDING
This project was supported by the Horizon2020 fund
for TBVAC2020 project PHC-08-2014, paid by the Swiss
Confederation SEFRI Contract 15.0033-4, 643381.
ACKNOWLEDGMENTS
We would like to acknowledge members of the Prof. Siegrist
laboratory, notably Paola Fontannaz, Stephane Grillet, as well
as the Flow Cytometry platform, and the experimental animal
facility at the University of Geneva for their contributions to
the study.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.01650/full#supplementary-material
REFERENCES
1. Belyakov IM, Ahlers JD. Comment on “Trafficking lymphocytes to
mucosal surfaces”. J Immunol. (2009) 182:1779. doi: 10.4049/jimmunol.
0990002
2. Kaufman DR, Barouch DH. Response to Comment on “Trafficking
of antigen-specific CD8+ T lymphocytes to mucosal surfaces
following intramuscular vaccination”. J Immunol. (2009) 182:1779–80.
doi: 10.4049/jimmunol.09-90003
3. Lai R, Afkhami S, Haddadi S, Jeyanathan M, Xing Z. Mucosal immunity and
novel tuberculosis vaccine strategies: Route of immunisation determined T-
cell homing to restricted lung mucosal compartments. Eur Respir Rev. (2015)
24:356–60. doi: 10.1183/16000617.00002515
4. Samaha H, Pignata A, Fousek K, Ren J, Lam FW, Stossi F, et al. A homing
system targets therapeutic T cells to brain cancer. Nature. (2018) 561:331–7.
doi: 10.1038/s41586-018-0499-y
5. Agace WW. Tissue-tropic effector T cells: generation and targeting
opportunities. Nat Rev Immunol. (2006) 6:682–92. doi: 10.1038/nri1869
6. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper
TS. Resident memory T cells (TRM) are abundant in human lung:
diversity, function, and antigen specificity. PLoS ONE. (2011) 6:e16245.
doi: 10.1371/journal.pone.0016245
7. D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F.
Chemokines and their receptors guiding T lymphocyte recruitment in
lung inflammation. Am J Respir Crit Care Med. (2001) 164:1266–75.
doi: 10.1164/ajrccm.164.7.2103011
8. Ainslie MP, McNulty CA, Huynh T, Symon FA, Wardlaw AJ.
Characterisation of adhesion receptors mediating lymphocyte adhesion
to bronchial endothelium provides evidence for a distinct lung homing
pathway. Thorax. (2002) 57:1054–9. doi: 10.1136/thorax.57.12.1054
9. Lee LN, Ronan EO, de Lara C, Franken KLMC, Ottenhoff THM, Tchilian EZ,
et al. CXCR6 is a marker for protective antigen-specific cells in the lungs after
intranasal immunization againstMycobacterium tuberculosis. Infect Immun.
(2011) 79:3328–37. doi: 10.1128/IAI.01133-10
10. Tager AM, Bromley SK,Medoff BD, Islam SA, Bercury SD, Friedrich EB, et al.
Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment.Nat
Immunol. (2003) 4:982–90. doi: 10.1038/ni970
11. Ferguson AR, Engelhard VH. CD8T cells activated in distinct
lymphoid organs differentially express adhesion proteins and coexpress
multiple chemokine receptors. J Immunol. (2010) 184:4079–86.
doi: 10.4049/jimmunol.0901903
12. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al.
Human tissue-resident memory T cells are defined by core transcriptional
and functional signatures in lymphoid and mucosal sites. Cell Rep. (2017)
20:2921–34. doi: 10.1016/j.celrep.2017.08.078
13. Arlehamn CL, Seumois G, Gerasimova A, Huang C, Fu Z, Yue X,
et al. Transcriptional profile of tuberculosis antigen–specific T cells
reveals novel multifunctional features. J Immunol. (2014) 193:2931–40.
doi: 10.4049/jimmunol.1401151
14. Xie JH, Nomura N, Lu M, Chen S-L, Koch GE, Weng Y, et al. Antibody-
mediated blockade of the CXCR3 chemokine receptor results in diminished
recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol.
(2003) 73:771–80. doi: 10.1189/jlb.1102573
15. Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-
active and CXCR3-active chemokines during human allergic pulmonary
late-phase reactions. J Allergy Clin Immunol. (2003) 112:930–4.
doi: 10.1016/j.jaci.2003.08.012
16. Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses
promote immunity to respiratory syncytial virus infection by augmenting
dendritic cell and CD8+ T cell efficacy. Eur J Immunol. (2008) 38:2168–79.
doi: 10.1002/eji.200838155
17. Sakai S, Kauffman KD, Schenkel JM, McBerry CC, Mayer-Barber KD,
Masopust D, et al. Cutting edge: control of Mycobacterium tuberculosis
infection by a subset of lung parenchyma-homing CD4T cells. J Immunol.
(2014) 192:2965–9. doi: 10.4049/jimmunol.1400019
18. Woodworth JS, Cohen SB,Moguche AO, Plumlee CR, Agger EM,Urdahl KB,
et al. Subunit vaccine H56/CAF01 induces a population of circulating CD4T
cells that traffic into the Mycobacterium tuberculosis-infected lung. Mucosal
Immunol. (2017) 10:555–64. doi: 10.1038/mi.2016.70
19. Stock A, Napolitani G, Cerundolo V. Intestinal DC in migrational
imprinting of immune cells. Immunol Cell Biol. (2013) 91:240–9.
doi: 10.1038/icb.2012.73
20. Krzysiek R, de Goër de Herve MG, Yang H, Taoufik Y. Tissue competence
imprinting and tissue residency of CD8T cells. Front Immunol. (2013) 4:283.
doi: 10.3389/fimmu.2013.00283
21. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt
M, et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic
cells. Nature. (2003) 424:88–93. doi: 10.1038/nature01726
22. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al.
DCs metabolize sunlight-induced vitamin D3 to “program” T cell attraction
to the epidermal chemokine CCL27. Nat Immunol. (2007) 8:285–93.
doi: 10.1038/ni1433
23. Edele F, Molenaar R, Gu D, Dudda JC, Jakob T, Homey B, et al.
Cutting edge: instructive role of peripheral tissue cells in the imprinting
of T cell homing receptor patterns 1. J Immunol. (2008) 181:3745–9.
doi: 10.4049/jimmunol.181.6.3745
24. Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, et al. Human
CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal
effector T cells via the cytokine TGF-b. Immunity. (2013) 38:818–30.
doi: 10.1016/j.immuni.2013.03.004
25. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR,
Terstappen LW. Differential regulation of the cutaneous lymphocyte-
associated antigen, a tissue-selective homing receptor for skin-homing T
cells. J Immunol. (1993) 150:1122–36.
26. Bakdash G, Vogelpoel LTC, Van Capel TMM, Kapsenberg ML, De Jong
EC. Retinoic acid primes human dendritic cells to induce gut-homing,
IL-10-producing regulatory T cells. Mucosal Immunol. (2015) 8:265–78.
doi: 10.1038/mi.2014.64
27. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J. Differential
homing commitments of antigen-specific T cells after oral or parenteral
immunization in humans. J Immunol. (1999) 162:5173–7.
28. Kantele A, Kantele JM, Savilahti E, WesterholmM, Arvilommi H, Lazarovits
A, et al. Homing potentials of circulating lymphocytes in humans depend on
the site of activation: oral, but not parenteral, typhoid vaccination induces
circulating antibody-secreting cells that all bear homing receptors directing
them to the gut. J Immunol. (1997) 158:574–9.
Frontiers in Immunology | www.frontiersin.org 15 July 2019 | Volume 10 | Article 1650
Pejoski et al. DC Activation of Lung-Trafficking T Cells
29. Baaten BJG, Cooper AM, Swain SL, Bradley LM. Location, location, location:
the impact of migratory heterogeneity on T cell function. Front Immunol.
(2013) 4:311. doi: 10.3389/fimmu.2013.00311
30. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent
costimulatory molecule for sustaining primary CD4T cell responses. J
Immunol. (1998) 161:6510–7.
31. Beier KC, Kallinich T, Hamelmann E. Master switches of T-cell
activation and differentiation. Eur Respir J. (2007) 29:804–12.
doi: 10.1183/09031936.00094506
32. White SJ, Underhill GH, Kaplan MH, Kansas GS. Cutting edge: differential
requirements for Stat4 in expression of glycosyltransferases responsible
for selectin ligand formation in Th1 cells. J Immunol. (2001) 167:628–31.
doi: 10.4049/jimmunol.167.2.628
33. Thatte J, Dabak V, Williams MB, Braciale TJ, Ley K. LFA-1 is required for
retention of effector CD8T cells in mouse lungs. Blood. (2003) 101:4916–22.
doi: 10.1182/blood-2002-10-3159
34. Mikhak Z, Strassner JP, Luster AD. Lung dendritic cells imprint T cell lung
homing and promote lung immunity through the chemokine receptor CCR4.
J Exp Med. (2013) 210:1855–69. doi: 10.1084/jem.20130091
35. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GRS, Perlman
H. Flow cytometric analysis of macrophages and dendritic cell subsets
in the mouse lung. Am J Respir Cell Mol Biol. (2013) 49:503–10.
doi: 10.1165/rcmb.2013-0086MA
36. Condon TV, Sawyer RT, Fenton MJ, Riches DW. Lung dendritic cells at
the innate-adaptive immune interface. J Leukoc Biol. (2011) 90:883–95.
doi: 10.1189/jlb.0311134
37. Sung S-SJ, Fu SM, Rose CE, Gaskin F, Ju S-T, Beaty SR. A major lung
CD103 (E)-7 integrin-positive epithelial dendritic cell population expressing
langerin and tight junction proteins. J Immunol. (2006) 176:2161–72.
doi: 10.4049/jimmunol.176.4.2161
38. Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C, et al.
The dendritic cell populations of mouse lymph nodes. J Immunol. (2001)
167:741–8. doi: 10.4049/jimmunol.167.2.741
39. Ballesteros-Tato A, Randall TD. Priming of T follicular helper cells by
dendritic cells. Immunol Cell Biol. (2014) 92:22–7. doi: 10.1038/icb.2013.62
40. Desch AN, Henson PM, Jakubzick C V. Pulmonary dendritic cell
development and antigen acquisition. Immunol Res. (2013) 55:178–86.
doi: 10.1007/s12026-012-8359-6
41. Lukens MV, Kruijsen D, Coenjaerts FEJ, Kimpen JLL, van Bleek GM.
Respiratory syncytial virus-induced activation and migration of respiratory
dendritic cells and subsequent antigen presentation in the lung-draining
lymph node. J Virol. (2009) 83:7235–43. doi: 10.1128/JVI.00452-09
42. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al.
Intravascular staining for discrimination of vascular and tissue leukocytes.
Nat Protoc. (2014) 9:209–22. doi: 10.1038/nprot.2014.005
43. Yu YRA, O’Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, et al. A
protocol for the comprehensive flow cytometric analysis of immune cells
in normal and inflamed murine non-lymphoid tissues. PLoS ONE. (2016)
11:e150606. doi: 10.1371/journal.pone.0150606
44. Budd RC, Cerottini JC, Horvath C, Bron C, Pedrazzini T, Howe RC, et al.
Distinction of virgin and memory T lymphocytes. Stable acquisition of
the Pgp-1 glycoprotein concomitant with antigenic stimulation. J Immunol.
(1987) 138:3120–9.
45. Pigni M, Ashok D, Stevanin M, Acha-Orbea H. Establishment and
characterization of a functionally competent type 2 conventional dendritic
cell line. Front Immunol. (2018) 9:1912. doi: 10.3389/fimmu.2018.01912
46. Fuertes Marraco SA, Grosjean F, Duval A, Rosa M, Lavanchy C, Ashok D,
et al. Novel murine dendritic cell lines: A powerful auxiliary tool for dendritic
cell research. Front Immunol. (2012) 3:331. doi: 10.3389/fimmu.2012.00331
47. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C,
Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in
vivo. Science. (2007) 315:107–11. doi: 10.1126/science.1136080
48. Slight SR, Rangel-moreno J, Gopal R, Lin Y, Junecko BAF, Mehra S, et al.
CXCR5+ T helper cells mediate protective immunity against tuberculosis. J
Clin Invest. (2013) 123:1–15. doi: 10.1172/JCI65728
49. Ruane D, Brane L, Reis BS, Cheong C, Poles J, Do Y, et al. Lung dendritic cells
induce migration of protective T cells to the gastrointestinal tract. J ExpMed.
(2013) 210:1871–88. doi: 10.1084/jem.20122762
50. Ruane D, Do Y, Brane L, Garg A, Bozzacco L, Kraus T, et al. A dendritic
cell targeted vaccine induces long-term HIV-specific immunity within the
gastrointestinal tract. J ExpMed. (2016) 9:1340–52. doi: 10.1038/mi.2015.133
51. Poles J, Alvarez Y, Hioe CE. Induction of intestinal immunity by mucosal
vaccines as a means of controlling HIV infection. AIDS Res Hum
Retroviruses. (2014) 30:1027–40. doi: 10.1089/aid.2014.0233
52. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of
lymphocytes. Immunity. (2002) 16:1–4. doi: 10.1016/S1074-7613(01)00261-8
53. Fu H, Ward EJ, Marelli-Berg FM. Mechanisms of T cell organotropism. Cell
Mol Life Sci. (2016) 73:3009–33. doi: 10.1007/s00018-016-2211-4
54. Turner DL, Farber DL. Mucosal resident memory CD4T cells in
protection and immunopathology. Front Immunol. (2014) 5:331.
doi: 10.3389/fimmu.2014.00331
55. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrançois L, Farber DL, et al.
Cutting edge: tissue-retentive lung memory CD4T cells mediate optimal
protection to respiratory virus infection. J Immunol. (2011) 187:5510–4.
doi: 10.4049/jimmunol.1102243
56. Laszlo G, Hathcock KS, Dickler HB, Hodes RJ. Characterization of a novel
cell-surface molecule expressed on subpopulations of activated T and B cells.
J Immunol. (1993) 150:5252–62.
57. Liu Y,Wenger RH, ZhaoM, Nielsen PJ. Distinct costimulatory molecules are
required for the induction of effector and memory cytotoxic T lymphocytes.
J Exp Med. (1997) 185:251–62. doi: 10.1084/jem.185.2.251
58. Yu Y, Smoligovets AA, Groves JT. Modulation of T cell signaling by the actin
cytoskeleton. J Cell Sci. (2013) 126:1049–58. doi: 10.1242/jcs.098210
59. Schittenhelm L, Hilkens CM, Morrison VL. β2 integrins as regulators of
dendritic cell, monocyte, and macrophage function. Front Immunol. (2017)
8:1866. doi: 10.3389/fimmu.2017.01866
60. Astarita JL, Acton SE, Turley JS. Podoplanin: emerging functions in
development, the immune system, and cancer. Front Immunol. (2012) 3:283.
doi: 10.3389/fimmu.2012.00283
61. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA.
Specific migratory dendritic cells rapidly transport antigen from the
airways to the thoracic lymph nodes. J Exp Med. (2001) 193:51–60.
doi: 10.1084/jem.193.1.51
62. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al.
Rapid and coordinated switch in chemokine receptor expression during
dendritic cell maturation. Eur J Immunol. (1998) 28:2760–9.
63. Plantinga M, Guilliams M, Vanheerswynghels M, Deswarte K, Branco-
Madeira F, Toussaint W, et al. Conventional and monocyte-derived
CD11b+ dendritic cells initiate and maintain T helper 2 cell-mediated
immunity to house dust mite allergen. Immunity. (2013) 38:322–35.
doi: 10.1016/j.immuni.2012.10.016
64. Jiao Z, Bedoui S, Brady JL, Walter A, Chopin M, Carrington EM, et al. The
closely related CD103+ dendritic cells (DCs) and lymphoid-resident CD8+
DCs differ in their inflammatory functions. PLoS ONE. (2014) 9:e91126.
doi: 10.1371/journal.pone.0091126
65. Masopust D, Schenkel JM. The integration of T cell migration, differentiation
and function. Nat Rev Immunol. (2013) 13:309–20. doi: 10.1038/
nri3442
66. Veldhoen M, Ferreira C. Influence of nutrient-derived metabolites on
lymphocyte immunity. Nat Med. (2015) 21:709–18. doi: 10.1038/nm.3894
67. Van Panhuys N. TCR signal strength alters T-DC activation and interaction
times and directs the outcome of differentiation. Front Immunol. (2016) 7:6.
doi: 10.3389/fimmu.2016.00006
68. Kim TS, Gorski SA, Hahn S, Murphy KM, Braciale TJ. Distinct dendritic
cell subsets dictate the fate decision between effector and memory CD8+
T cell differentiation by a CD24-dependent mechanism. Immunity. (2014)
40:400–13. doi: 10.1016/j.immuni.2014.02.004
69. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing
phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid
tissues. J Exp Med. (2002) 195:135–42. doi: 10.1084/jem.20011502
70. Kadmon G, Eckert M, Sammar M, Schachner M, Altevogt P. Nectadrin,
the heat-stable antigen, is a cell adhesion molecule. J Cell Biol. (1992)
118:1245–58. doi: 10.1083/jcb.118.5.1245
71. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of
CD24, a mucin-like adhesion molecule. J Mol Histol. (2003) 35:255–62.
doi: 10.1023/B:HIJO.0000032357.16261.c5
Frontiers in Immunology | www.frontiersin.org 16 July 2019 | Volume 10 | Article 1650
Pejoski et al. DC Activation of Lung-Trafficking T Cells
72. Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, et al. CD24
controls Src/STAT3 activity in human tumors. Cell Mol Life Sci. (2012)
69:3863–79. doi: 10.1007/s00018-012-1055-9
73. Li O, Zheng P, Liu Y. CD24 expression on T cells is required for optimal
T cell proliferation in lymphopenic host. J Exp Med. (2004) 200:1083–9.
doi: 10.1084/jem.20040779
74. Stutte S, Jux B, Esser C, Förster I. CD24a expression levels discriminate
langerhans cells from dermal dendritic cells inmurine skin and lymph nodes.
J Invest Dermatol. (2008) 128:1470–5. doi: 10.1038/sj.jid.5701228
75. Bofill M, Janossy G, Janossa M, Burford GD, Seymour GJ, Wernet P,
et al. Human B cell development. II. Subpopulations in the human fetus. J
Immunol. (1985) 134:1531–8.
76. Duperray C, Boiron JM, Boucheix C, Cantaloube JF, Lavabre-Bertrand T,
Attal M, et al. The CD24 antigen discriminates between pre-B and B cells
in human bone marrow. J Immunol. (1990) 145:3678–83.
77. Alegre ML. Costimulatory molecules as targets for the induction of
transplantation tolerance. Nephrol Dial Transplant. (1999) 14:322–32.
doi: 10.1093/ndt/14.2.322
78. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al.
IRF4 Transcription factor-dependent CD11b+ dendritic cells in human
and mouse control mucosal IL-17 cytokine responses. Immunity. (2013)
38:970–83. doi: 10.1016/j.immuni.2013.04.011
79. Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al.
Dendritic cells display subset and tissue-specific maturation dynamics over
human life. Immunity. (2017) 46:504–15. doi: 10.1016/j.immuni.2017.02.019
80. Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF,
et al. Enhancement of antigen-induced T-cell proliferation by soluble
CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA. (1994) 91:3082–6.
doi: 10.1073/pnas.91.8.3082
81. Vandenberg T, Kraal G. A function for the macrophage F4/80
molecule in tolerance induction. Trends Immunol. (2005) 26:506–9.
doi: 10.1016/j.it.2005.07.008
82. Pfistershammer K, Klauser C, Pickl WF, Stöckl J, Leitner J, Zlabinger G,
et al. No evidence for dualism in function and receptors: PD-L2/B7-DC is
an inhibitory regulator of human T cell activation. Eur J Immunol. (2006)
36:1104–13. doi: 10.1002/eji.200535344
83. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-
Lindbom B, et al. Essential role for CD103 in the T cell-mediated
regulation of experimental colitis. J Exp Med. (2005) 202:1051–61.
doi: 10.1084/jem.20040662
84. Johansson-Lindbom B, Svensson M, Pabst O, Förster R, Marquez G,
Palmqvist C, et al. Functional specialization of gut CD103+ dendritic cells
in the regulation of tissue-selective T cell homing. J Exp Med. (2005)
202:1063–73. doi: 10.1084/jem.20051100
85. Dudda JC, Lembo A, Bachtanian E, Huehn J, Siewert C, Hamann A, et al.
Dendritic cells govern induction and reprogramming of polarized tissue-
selective homing receptor patterns of T cells: important roles for soluble
factors and tissue microenvironments. Eur J Immunol. (2005) 35:1056–65.
doi: 10.1002/eji.200425817
86. Bakdash G, Sittig SP, van Dijk T, Figdor CG, de Vries IJM. The nature of
activatory and tolerogenic dendritic cell-derived signal II. Front Immunol.
(2013) 4:53. doi: 10.3389/fimmu.2013.00053
87. Gretz JE, Norbury CC, Anderson AO, Proudfoot AEI, Shaw S. Lymph-
borne chemokines and other low molecular weight molecules reach high
endothelial venules via specialized conduits while a functional barrier limits
access to the lymphocyte microenvironments in lymph node cortex. J Exp
Med. (2000) 192:1425–40. doi: 10.1084/jem.192.10.1425
88. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al.
Dendritic cells require a systemic type I interferon response to mature and
induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. (2009)
206:1589–602. doi: 10.1084/jem.20090247
89. Flores-Langarica A, Meza-Perez S, Calderon-Amador J, Estrada-Garcia T,
Macpherson G, Lebecque S, et al. Network of dendritic cells within the
muscular layer of the mouse intestine. Proc Natl Acad Sci USA. (2005)
102:19039–44. doi: 10.1073/pnas.0504253102
90. Zhang Y, Wu Y, Qi H, Gong H, Xu E, Li S, et al. A new antagonist for CCR4
attenuates allergic lung inflammation in a mouse model of asthma. Sci Rep.
(2017) 7:15038. doi: 10.1038/s41598-017-11868-9
91. Faustino L, Fonseca DMD, Takenaka MC, Mirotti L, Florsheim EB,
Guereschi MG, et al. Regulatory T cells migrate to airways via CCR4 and
attenuate the severity of airway allergic inflammation. J Immunol. (2013)
190:2614–21. doi: 10.4049/jimmunol.1202354
92. Lindenstrøm T, Woodworth J, Dietrich J, Aagaard C, Andersen P, Agger
EM. Vaccine-induced Th17 cells are maintained long-term postvaccination
as a distinct and phenotypically stable memory subset. Infect Immun. (2012)
80:3533–44. doi: 10.1128/IAI.00550-12
93. Christensen D, Mortensen R, Rosenkrands I, Dietrich J, Andersen P.
Vaccine-induced Th17 cells are established as resident memory cells in the
lung and promote local IgA responses.Mucosal Immunol. (2017) 10:260–70.
doi: 10.1038/mi.2016.28
94. Nikitina IY, Panteleev AV, Kosmiadi GA, Serdyuk YV, Nenasheva TA,
Nikolaev AA, et al. Th1, Th17, and Th1Th17 lymphocytes during
tuberculosis: Th1 lymphocytes predominate and appear as low-
differentiated CXCR3+ CCR6+ cells in the blood and highly differentiated
CXCR3+/− CCR6− cells in the lungs. J Immunol. (2018) 200:1–14.
doi: 10.4049/jimmunol.1701424
95. Orme IM, Robinson RT, Cooper AM. The balance between protective and
pathogenic immune responses in the TB-infected lung.Nat Immunol. (2014)
16:57–63. doi: 10.1038/ni.3048
96. Mildner A, Jung S. Development and function of dendritic cell subsets.
Immunity. (2014) 40:642–56. doi: 10.1016/j.immuni.2014.04.016
97. Ruane D, Chorny A, Lee H, Faith J, Pandey G, Shan M, et al. Microbiota
regulate the ability of lung dendritic cells to induce IgA class-switch
recombination and generate protective gastrointestinal immune responses.
J Exp Med. (2016) 213:53–73. doi: 10.1084/jem.20150567
98. Palkola NV, Pakkanen SH, Kantele JM, Pakarinen L, Puohiniemi R,
Kantele A. Differences in homing potentials of streptococcus pneumoniae-
specific plasmablasts in pneumococcal pneumonia and after pneumococcal
polysaccharide and pneumococcal conjugate vaccinations. J Infect Dis.
(2015) 212:1279–87. doi: 10.1093/infdis/jiv208
99. Lycke N. Recent progress in mucosal vaccine development: potential and
limitations. Nat Rev Immunol. (2012) 12:592–605. doi: 10.1038/nri3251
100. Iwasaki A. Exploiting mucosal immunity for antiviral
vaccines. Annu Rev Immunol. (2016) 34:575–608.
doi: 10.1146/annurev-immunol-032414-112315
101. Aoshi T. Modes of action for mucosal vaccine adjuvants. Viral Immunol.
(2017) 30:463–70. doi: 10.1089/vim.2017.0026
102. Kodama S, Hirano T, Noda K, Abe N, Suzuki M. A single nasal
dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal
application, enhances nontypeable Haemophilus influenzae-specific long-
term mucosal immune responses in the nasopharynx. Vaccine. (2010)
28:2510–6. doi: 10.1016/j.vaccine.2010.01.043
103. Veazey RS, Siddiqui A, Klein K, Buffa V, Fischetti L, Doyle-Meyers
L, et al. Evaluation of mucosal adjuvants and immunization routes
for the induction of systemic and mucosal humoral immune
responses in macaques. Hum Vaccines Immunother. (2015) 11:2913–22.
doi: 10.1080/21645515.2015.1070998
104. Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, et al. A
combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits
NALT dendritic cells for prolonged mucosal immunity. Vaccine. (2008)
26:4849–59. doi: 10.1016/j.vaccine.2008.06.091
105. Perdomo C, Zedler U, Kühl AA, Lozza L, Saikali P, Sander LE,
et al. Mucosal BCG vaccination induces protective lung-resident
memory T cell populations against tuberculosis. MBio. (2016) 7:1–11.
doi: 10.1128/mBio.01686-16
106. Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA,
Graham BS. Intranasal administration of RSV antigen-expressing MCMV
elicits robust tissue-resident effector and effector memory CD8+ T
cells in the lung. Mucosal Immunol. (2016) 2:1–10. doi: 10.1038/mi.
2016.48
107. Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto
PA, et al. A mucosal vaccine against Chlamydia trachomatis generates
two waves of protective memory T cells. Science. (2015) 348:1331–45.
doi: 10.1126/science.aaa8205
108. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L,
et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to
Frontiers in Immunology | www.frontiersin.org 17 July 2019 | Volume 10 | Article 1650
Pejoski et al. DC Activation of Lung-Trafficking T Cells
inhibit the growth of mucosal tumors. Sci Transl Med. (2013) 5:1–12.
doi: 10.1126/scitranslmed.3004888
109. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of
the Inactivated Intranasal Influenza Vaccine and the Risk of Bell’s Palsy in
Switzerland.N Engl J Med. (2004) 350:896–903. doi: 10.1056/NEJMoa030595
110. Hatley R, Pritchard J. Devices and formulations for pulmonary
vaccination. Expert Opin Drug Deliv. (2013) 10:1593–5.
doi: 10.1517/17425247.2013.833181
111. Lewis DJM, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al.
Transient facial nerve paralysis (Bell’s Palsy) following intranasal delivery of a
genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE.
(2009) 4:e6999. doi: 10.1371/journal.pone.0006999
112. Bajaña S, Turner S, Paul J, Ainsua-Enrich E, Kovats S. IRF4 and IRF8 Act
in CD11c+ cells to regulate terminal differentiation of lung tissue dendritic
cells. J Immunol. (2016) 196:1666–77. doi: 10.4049/jimmunol.1501870
113. Martín-Fontecha A, Sebastiani S, Höpken UE, Uguccioni M, Lipp M,
Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining
lymph node. J Exp Med. (2003) 198:615–21. doi: 10.1084/jem.20030448
114. Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit
J, et al. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal
surfaces following intramuscular vaccination. J Immunol. (2008) 181:4188–
98. doi: 10.4049/jimmunol.181.6.4188
115. Lin SW, Cun AS, Harris-McCoy K, Ertl HC. Intramuscular
rather than oral administration of replication-defective adenoviral
vaccine vector induces specific CD8+ T cell responses in the
gut. Vaccine. (2007) 25:2187–93. doi: 10.1016/j.vaccine.2006.
11.044
116. Christensen D, Bøllehuus Hansen L, Leboux R, Jiskoot W, Christensen
JP, Andersen P, et al. A liposome-based adjuvant containing two
delivery systems with the ability to induce mucosal immunoglobulin
A following a parenteral immunization. ACS Nano. (2019) 13:1116–26.
doi: 10.1021/acsnano.8b05209
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Pejoski, Ballester, Auderset, Vono, Christensen, Andersen,
Lambert and Siegrist. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 18 July 2019 | Volume 10 | Article 1650
